MedTrace Logo

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2023-04-06

Study results available
· View outcomes & findings →

Summary

A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts

Conditions

  • Genital Warts
  • Perianal Warts

Interventions

DRUG

NVN1000 8% Gel

once and twice daily

DRUG

NVN1000 16%

once daily

DRUG

Vehicle

placebo comparator

DRUG

NVN1000 24%

once daily

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • Joyce Rico, MD · Novan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-12
Primary Completion
2016-10-31
Completion
2016-10-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462187 on ClinicalTrials.gov